Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, Akins NR, Stuart AB, Wan YH, Feng J, Nelson RE, Singh S, Cohen KW, McElrath MJ, Englund JA, Chu HY, Pancera M, McGuire AT, Stamatatos L. Seydoux E, et al. Among authors: chu hy. bioRxiv [Preprint]. 2020 May 12:2020.05.12.091298. doi: 10.1101/2020.05.12.091298. bioRxiv. 2020. PMID: 32511342 Free PMC article. Updated. Preprint.
Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak.
Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, Amanat F, Walls AC, Wolf CR, Murphy M, Pettie D, Carter L, Qin X, King NP, Veesler D, Krammer F, Dickerson JA, Chu HY, Englund JA, Bloom JD. Dingens AS, et al. Among authors: chu hy. medRxiv [Preprint]. 2020 Jun 30:2020.05.26.20114124. doi: 10.1101/2020.05.26.20114124. medRxiv. 2020. PMID: 32511483 Free PMC article. Updated. Preprint.
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2.
Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Walls AC, et al. Among authors: chu hy. bioRxiv [Preprint]. 2020 Aug 12:2020.08.11.247395. doi: 10.1101/2020.08.11.247395. bioRxiv. 2020. PMID: 32817941 Free PMC article. Updated. Preprint.
Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak.
Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, Eguia R, Amanat F, Walls AC, Wolf CR, Murphy M, Pettie D, Carter L, Qin X, King NP, Veesler D, Krammer F, Dickerson JA, Chu HY, Englund JA, Bloom JD. Dingens AS, et al. Among authors: chu hy. Nat Commun. 2020 Sep 1;11(1):4378. doi: 10.1038/s41467-020-18178-1. Nat Commun. 2020. PMID: 32873791 Free PMC article.
Cross-Sectional Prevalence of SARS-CoV-2 Among Skilled Nursing Facility Employees and Residents Across Facilities in Seattle.
Weil AA, Newman KL, Ong TD, Davidson GH, Logue J, Brandstetter E, Magedson A, McDonald D, McCulloch DJ, Neme S, Lewis J, Duchin JS, Zhong W, Starita LM, Bedford T, Roxby AC, Chu HY. Weil AA, et al. Among authors: chu hy. J Gen Intern Med. 2020 Nov;35(11):3302-3307. doi: 10.1007/s11606-020-06165-7. Epub 2020 Sep 1. J Gen Intern Med. 2020. PMID: 32875494 Free PMC article.
The Seattle Flu Study: a multiarm community-based prospective study protocol for assessing influenza prevalence, transmission and genomic epidemiology.
Chu HY, Boeckh M, Englund JA, Famulare M, Lutz B, Nickerson DA, Rieder M, Starita LM, Adler A, Brandstetter E, Frazer CD, Han PD, Gulati RK, Hadfield J, Jackson M, Kiavand A, Kimball LE, Lacombe K, Newman K, Sibley TR, Logue JK, Lyon VR, Wolf CR, Zigman Suchsland M, Shendure J, Bedford T. Chu HY, et al. BMJ Open. 2020 Oct 7;10(10):e037295. doi: 10.1136/bmjopen-2020-037295. BMJ Open. 2020. PMID: 33033018 Free PMC article.
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
Walls AC, Fiala B, Schäfer A, Wrenn S, Pham MN, Murphy M, Tse LV, Shehata L, O'Connor MA, Chen C, Navarro MJ, Miranda MC, Pettie D, Ravichandran R, Kraft JC, Ogohara C, Palser A, Chalk S, Lee EC, Guerriero K, Kepl E, Chow CM, Sydeman C, Hodge EA, Brown B, Fuller JT, Dinnon KH 3rd, Gralinski LE, Leist SR, Gully KL, Lewis TB, Guttman M, Chu HY, Lee KK, Fuller DH, Baric RS, Kellam P, Carter L, Pepper M, Sheahan TP, Veesler D, King NP. Walls AC, et al. Among authors: chu hy. Cell. 2020 Nov 25;183(5):1367-1382.e17. doi: 10.1016/j.cell.2020.10.043. Epub 2020 Oct 31. Cell. 2020. PMID: 33160446 Free PMC article.
434 results